
|Videos|July 7, 2021
Why Research Assessing Dapagliflozin Advanced From Cardiorenal Effects to Prevention, Organ Protection
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.
Advertisement
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod explained why the research assessing dapagliflozin advanced from cardiorenal effects to prevention and organ protection.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
World Lung Cancer Day: Pharmacists Are Essential Across Prevention, Screening, and Treatment
2
A Pharmacist's Guide to Probiotics for Preventing Traveler’s Diarrhea
3
July 2026 in Pain Management: 10 Developments That Advanced and Challenged Patient Care
4
A Pharmacist’s Guide to Modern Menopause Management in 2026
5





































































































